Elixiron Immunotherapeutics Receives Grant From the Alzheimer's Association to Trial Microglia-Targeting Immunotherapy
12 juil. 2022 11h01 HE
|
Elixiron Immunotherapeutics
SAN FRANCISCO, July 12, 2022 (GLOBE NEWSWIRE) -- Elixiron Immunotherapeutics, a clinical stage drug development company announced today that it has received a new grant from the Alzheimer's...
Global Systemic Lupus Erythematosus (SLE) Market Report 2022-2026: Featuring Pfizer, AstraZeneca, GlaxoSmithKline and Others
29 juin 2022 06h48 HE
|
Research and Markets
Dublin, June 29, 2022 (GLOBE NEWSWIRE) -- The "Global Systemic Lupus Erythematosus (SLE) Market: Analysis By Product Type, By Route of Administration, By End User, By Region Size and Trends with...
Does Early Life Inflammation Contribute to the Risk for Developing Psychiatric Conditions?
07 juin 2022 09h50 HE
|
Brain & Behavior Research Foundation
New York, June 07, 2022 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Does Early Life Inflammation Contribute to the Risk for Developing...
CORRECTION: Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights
12 mai 2022 10h47 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, May 12 by Evelo Biosciences, Inc. (Nasdaq: EVLO), please note that in the first sentence...
180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology
29 avr. 2022 18h32 HE
|
180 Life Sciences Corp.
The study achieved the primary endpoint of reduction in nodule hardness at 12 months and secondary endpoint of reduction in nodule size at multiple time points including 12 monthsThe treatment arm...
Evelo Biosciences Appoints John Maraganore, Ph.D. and Tassos Gianakakos as Strategic Advisors
21 avr. 2022 06h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...
Evelo Biosciences Provides Updated Guidance on Advancing Clinical Inflammation Programs
14 avr. 2022 06h00 HE
|
Evelo Biosciences, Inc.
–Guidance on registration trials for EDP1815 in psoriasis expected in 3Q 2022––Data from initial cohort of patients in Phase 2 trial of EDP1815 in atopic dermatitis expected 1Q 2023––Faster release...
Flow Therapy Adds World-Renowned Cardiologist Timothy D. Henry to Board of Directors
06 avr. 2022 09h00 HE
|
Flow Therapy
FORT WORTH, Texas, April 06, 2022 (GLOBE NEWSWIRE) -- World-renowned cardiologist Timothy D. Henry, MD, FACC, MSCAI, has joined Flow Therapy's Board of Directors. Dr. Henry is the Lindner Family...
Evelo Biosciences Announces Appointments of Jose-Carlos Gutiérrez-Ramos and Tonya Williams to Board of Directors
06 avr. 2022 06h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...
IBN (InvestorBrandNetwork) Coverage Initiated for Silo Pharma Inc.
30 mars 2022 08h30 HE
|
Silo Pharma Inc.
NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with...